获取途径

作者

Ping Ma, Zhihuan Zhang, Mengying Qian, Hao Jiang, Yu Zhao, Qing Shan, Xia Liu, Tianming Yao, Jinmin Guo

作者单位

Affiliations ¹ Department of Clinical Pharmacy, The 960th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Jinan, Shandong, China. ² Department of Mathematics, University of Shandong, Jinan, Shandong, China. ³ Department of Pharmacy, Shandong Second Medical University, Weifang, Shandong, China. ⁴ Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. ⁵ Department of Clinical Pharmacy, School of Pharmacy, Naval Medical University, Shanghai 200082, China. ⁶ The 964th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, 4799 Xi 'an Road, Changchun 130062, Jilin, China. ⁷ Department of Clinical Pharmacy, The 960th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, 25 Shi Fan Road, Jinan 25003, Shandong, China. ⁸ Jinan Key Laboratory of Individualised Clinical Drug Safety Monitoring and Pharmacovigilance Research, Jinan 25003, Shandong, China.

刊名

Therapeutic advances in medical oncology

年份

2024

卷号

Vol.16

ISSN

1758-8340

关键词

anti-hypertensive drugs calcium channel blocker cancer survival immune checkpoint inhibitors renin–angiotensin system inhibitor.

摘要

Background: The efficacy of immune checkpoint inhibitors in cancer patients taking anti-hypertensive drugs is still not well established. Objective: To elucidate the effect of anti-hypertensive drugs on the clinical outcome of cancer patients receiving immunotherapy. Design: A retrospective cohort study and meta-analysis. Method: We conducted a real-world retrospective study of cancer patients treated with immunotherapy at two tertiary centers between January 2019 and June 2023, with primary ou...更多

Background: The efficacy of immune checkpoint inhibitors in cancer patients taking anti-hypertensive drugs is still not well established. Objective: To elucidate the effect of anti-hypertensive drugs on the clinical outcome of cancer patients receiving immunotherapy. Design: A retrospective cohort study and meta-analysis. Method: We conducted a real-world retrospective study of cancer patients treated with immunotherapy at two tertiary centers between January 2019 and June 2023, with primary outcomes being overall survival and progression-free survival . In addition, we performed a meta-analysis to synthesize currently relevant clinical studies. Results: A retrospective clinical study of 336 patients from 2 centers suggested that the use of anti-hypertensive drugs was related to a preferable OS = 0.55, 95% confidence interval : 0.33-0.90) compared to non-users. For PFS, no significant correlation was detected . Further analysis revealed that renin-angiotensin system inhibitor and calcium channel blocker have a synergistic effect with ICIs. In addition, subgroup analysis found that the benefits of RASi or CCB in combination with ICIs are greater in women or patients ⩾65 years of age. There was better disease control in lung cancer patients using RASi, and a significantly longer OS was observed in patients with gastrointestinal tumors taking CCB. Meta-analysis suggested that anti-hypertensive drugs were associated with improved OS, but only the combination of RASi and immunotherapy showed a synergistic effect. No significant correlation with OS was found for other anti-hypertensive drugs, and there was no overall positive effect on PFS. Conclusion: Our study found that use of anti-hypertensive drugs, particularly RASi or CCB, was associated with improved OS in patients undergoing immunotherapy. The synergistic effects of RASi or CCB with ICIs were more pronounced in females or elderly. RASi or CCB exhibited different benefits in various types of tumors. These findings provide valuable insights for treating cancer patients with hypertension.收起

文献类型

期刊

浏览量

5